Leung Alexander Kc, Barankin Benjamin, Lam Joseph M, Leong Kin Fon, Hon Kam Lun
Department of Pediatrics, The University of Calgary and The Alberta Children's Hospital, Calgary, Alberta, Canada.
Toronto Dermatology Centre, Toronto, Ontario, Canada.
Drugs Context. 2023 Jun 29;12. doi: 10.7573/dic.2023-5-1. eCollection 2023.
Tinea pedis is one of the most common superficial fungal infections of the skin, with various clinical manifestations. This review aims to familiarize physicians with the clinical features, diagnosis and management of tinea pedis.
A search was conducted in April 2023 in PubMed Clinical Queries using the key terms 'tinea pedis' OR 'athlete's foot'. The search strategy included all clinical trials, observational studies and reviews published in English within the past 10 years.
Tinea pedis is most often caused by and . It is estimated that approximately 3% of the world population have tinea pedis. The prevalence is higher in adolescents and adults than in children. The peak age incidence is between 16 and 45 years of age. Tinea pedis is more common amongst males than females. Transmission amongst family members is the most common route, and transmission can also occur through indirect contact with contaminated belongings of the affected patient. Three main clinical forms of tinea pedis are recognized: interdigital, hyperkeratotic (moccasin-type) and vesiculobullous (inflammatory). The accuracy of clinical diagnosis of tinea pedis is low. A KOH wet-mount examination of skin scrapings of the active border of the lesion is recommended as a point-of-care testing. The diagnosis can be confirmed, if necessary, by fungal culture or culture-independent molecular tools of skin scrapings. Superficial or localized tinea pedis usually responds to topical antifungal therapy. Oral antifungal therapy should be reserved for severe disease, failed topical antifungal therapy, concomitant presence of onychomycosis or in immunocompromised patients.
Topical antifungal therapy (once to twice daily for 1-6 weeks) is the mainstay of treatment for superficial or localized tinea pedis. Examples of topical antifungal agents include allylamines (e.g. terbinafine), azoles (e.g. ketoconazole), benzylamine, ciclopirox, tolnaftate and amorolfine. Oral antifungal agents used for the treatment of tinea pedis include terbinafine, itraconazole and fluconazole. Combined therapy with topical and oral antifungals may increase the cure rate. The prognosis is good with appropriate antifungal treatment. Untreated, the lesions may persist and progress.
足癣是最常见的皮肤浅表真菌感染之一,有多种临床表现。本综述旨在使医生熟悉足癣的临床特征、诊断和治疗。
2023年4月在PubMed临床查询中使用关键词“足癣”或“运动员脚”进行检索。检索策略包括过去10年内以英文发表的所有临床试验、观察性研究和综述。
足癣最常由 和 引起。据估计,世界人口中约3%患有足癣。青少年和成年人中的患病率高于儿童。发病高峰年龄在16至45岁之间。足癣在男性中比女性更常见。家庭成员之间的传播是最常见的途径,也可通过间接接触受感染患者的污染物品而传播。足癣主要有三种临床类型:指间型、角化过度型(拖鞋型)和水疱大疱型(炎症型)。足癣的临床诊断准确性较低。建议对病变活动边缘的皮肤刮屑进行氢氧化钾湿片检查作为即时检测。如有必要,可通过真菌培养或皮肤刮屑的非培养分子工具来确诊。浅表或局限性足癣通常对局部抗真菌治疗有反应。口服抗真菌治疗应保留用于重症、局部抗真菌治疗失败、同时存在甲癣或免疫功能低下的患者。
局部抗真菌治疗(每天1至2次,持续1 - 6周)是浅表或局限性足癣治疗的主要方法。局部抗真菌药物的例子包括烯丙胺类(如特比萘芬)、唑类(如酮康唑)、苄胺、环吡酮、萘替芬和阿莫罗芬。用于治疗足癣的口服抗真菌药物包括特比萘芬、伊曲康唑和氟康唑。局部和口服抗真菌药物联合治疗可能会提高治愈率。进行适当的抗真菌治疗,预后良好。未经治疗,病变可能持续并进展。